TrialRadiology. Imaging cancer2022

Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors.

Vincent Vandecaveye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.